Navigation Links
BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products
Date:4/7/2009

ARLINGTON, Va., April 7 /PRNewswire/ -- BioInformatics, LLC announces the pending release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. As a result of the March 9, 2009 reversal of the 2001 restrictions on federal funding of human embryonic stem cell research, suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell products market. In this report, BioInformatics, LLC (http://www.gene2drug.com), the premier research and advisory firm serving the life science market, fielded a detailed 60-question survey to scientists worldwide about their current--and planned--areas of stem cell research, usage of stem cell products and preferred suppliers.

The report is scheduled to release at the end of April, and is available at pre-release pricing until May 17, 2009. This special pricing is at a significant reduction off the regular pricing which will take effect on Monday, May 18, 2009.

Scientists involved in stem cell research, whether they are more focused on understanding basic stem cell biology, developing cell-based therapies using stem cells, or using stem cells to improve drug target validation and toxicology screening, rely on stem cell research products from major life science suppliers as well as more niche stem cell companies. In this report, scientists specify percentage of stem cell culture products purchased from each of the following suppliers:

    ATCC
    BD Biosciences (a part of Becton, Dickinson and Co., NYSE:  BDX)
    CellGenix
    Life Technologies (Nasdaq:  LIFE)
    Lonza (SWX: LONN)
    Millipore (NYSE:  MIL)
    Miltenyi Biotec
    R&D Systems (division of TECHNE Corp., Nasdaq:  TECH)
    Sigma-Aldrich (divisions: SAFC Biosciences, Nasdaq:  SIAL)
    Stem Cell Sciences (AIM:  STEM)
    Stemcell Technologies
    Thermo Fisher Scientific (Hyclone, NYSE:  TMO)
    Zen Bio

Life science suppliers can use this study to determine areas poised for growth (i.e., media, sera, supplements and cell lines) in the stem cell research products market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure a leading position in this expanding market. The report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers.

"There is tremendous excitement, especially in the academic community, over the recent Executive Order signed by President Barack Obama rescinding the restriction on federal funding of human embryonic stem cell research," notes Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. "However, the exploration of induced pluripotent stem cells and the pursuit of cell-based therapies and drug discovery and development research using adult human stem cells continues to provide great promise." Dr. Zemlo has been the senior analyst on over 80 syndicated market research reports, and consulted with multiple stem cell product vendors to optimize the relevance of this study with regards to the current stem cell research market. According to Zemlo, the report provides insights into the origins and sources of stem cells currently used in the lab (adult, embryonic, induced and pluripotent), and those likely to be used over the next several years -- in addition to differentiated cell types and associated diseases under investigation -- allowing suppliers to anticipate the types of stem cell culture products labs will need to purchase.

To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/201/.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 42,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

    For more information contact:

    Mary Follin
    Manager, Marketing/Sales
    BioInformatics, LLC
    2111 Wilson Blvd., Suite 250
    Arlington, VA  22201
    703.778.3080 x13 (phone)
    m.follin@gene2drug.com
   http://www.gene2drug.com/


'/>"/>
SOURCE BioInformatics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioInformatics, LLC, A Recognized Sponsor of First Annual Consumer Genetics Show in Boston, June 9-11, 2009
2. Virginia Tech Report Has National Importance
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
5. Haemacure Reports Third Quarter 2007 Results
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Biotech Finishes on a High in August, Burrill Report Says
8. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. MDS Reports Third Quarter 2007 Results
11. First New York/New Jersey Health Care Report Card Released
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: